Tioga Pharmaceuticals, Inc. develops therapies for the treatment of pruritus in atopic dermatitis. It also offers therapies to treat pruritus associated with various other conditions, including psoriasis, end-stage renal disease, liver diseases (cholestatic disease and primary biliary cirrhosis), and hyperthyroidism. The company was founded in 2005 and is based in San Diego, California.
4747 Executive Drive
San Diego, CA 92121
Founded in 2005
Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis
Jun 11 15
Tioga Pharmaceuticals announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States. Because of its mechanism of action, asimadoline has the potential to treat pruritus associated with a variety of conditions, including atopic dermatitis, psoriasis, end-stage renal disease, liver diseases such as cholestatic disease and primary biliary cirrhosis, malignancies, adverse drug effects, and certain orphan diseases. Chronic pruritus, which is defined as pruritus lasting six weeks or more, is associated with significant decrease in quality of life, including impact on sleep, anxiety, depression, and ability to work and lacks effective treatment options. Chronic pruritus is estimated to occur in approximately 20% of the general population (lifetime prevalence), with a very high incidence in certain dermatological and systemic conditions. The kappa-opioid system plays a pivotal role in the sensory transmission and processing of itch sensation from the skin to the brain. Animal models of chronic pruritus have demonstrated decreased kappa-opioid receptor activation or down regulation, coupled with increased mu-opioid receptor activation. Asimadoline has demonstrated efficacy in animal models of pruritus by significantly reducing the frequency of scratching induced by intra-dermally injected Substance P and significantly inhibiting scratching behavior induced by intra-dermally injected histamine or dinitrofluorobenzene.
Tioga Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Tioga Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.